Catalysis and Peptide Research Unit, School of Health Sciences and School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa.
School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa.
J Labelled Comp Radiopharm. 2024 Sep;67(11):360-374. doi: 10.1002/jlcr.4120. Epub 2024 Aug 8.
This research presents the development of positron emission tomography (PET) radiotracers for detecting Mycobacterium tuberculosis (MTB) for the diagnosis and monitoring of tuberculosis. Two phage display-derived peptides with proven selective binding to MTB were identified for development into PET radiopharmaceuticals: H8 (linear peptide) and PH1 (cyclic peptide). We sought to functionalize H8/PH1 with NODASA, a bifunctional chelator that allows complexation of PET-compatible radiometals such as gallium-68. Herein, we report on the chelator functionalization, optimized radiosynthesis, and assessment of the radiopharmaceutical properties of [Ga]Ga-NODASA-H8 and [Ga]Ga-NODASA-PH1. Robust radiolabeling was achieved using the established routine method, indicating consistent production of a radiochemically pure product (RCP ≥ 99.6%). For respective [Ga]Ga-NODASA-H8 and [Ga]Ga-NODASA-PH1, relatively high levels of decay-corrected radiochemical yield (91.2% ± 2.3%, 86.7% ± 4.0%) and apparent molar activity (A, 3.9 ± 0.8 and 34.0 ± 5.3 GBq/μmol) were reliably achieved within 42 min, suitable for imaging purposes. Notably, [Ga]Ga-NODASA-PH1 remained stable in blood plasma for up to 2 h, while [Ga]Ga-NODASA-H8 degraded within 30 min. For both Ga peptides, minimal whole-blood cell binding and plasma protein binding were observed, indicating a favorable pharmaceutical behavior. [Ga]Ga-NODASA-PH1 is a promising candidate for further in vitro/in vivo evaluation as a tuberculosis-specific infection imaging agent.
本研究开发了正电子发射断层扫描(PET)示踪剂,用于检测结核分枝杆菌(MTB),以诊断和监测结核病。已经确定了两种经过验证的噬菌体展示衍生肽,它们对 MTB 具有选择性结合,可开发为 PET 放射性药物:H8(线性肽)和 PH1(环状肽)。我们试图用 NODASA 对 H8/PH1 进行功能化,NODASA 是一种双功能螯合剂,允许与镓-68 等 PET 兼容的放射性金属络合。在此,我们报告了螯合剂的功能化、优化的放射合成以及 [Ga]Ga-NODASA-H8 和 [Ga]Ga-NODASA-PH1 的放射性药物特性评估。使用既定的常规方法实现了稳定的放射性标记,表明始终如一的生产出放射性化学纯产物(RCP≥99.6%)。对于各自的 [Ga]Ga-NODASA-H8 和 [Ga]Ga-NODASA-PH1,在 42 分钟内可靠地实现了相对较高的放射性化学产率(91.2%±2.3%,86.7%±4.0%)和表观摩尔活度(A,3.9±0.8 和 34.0±5.3GBq/μmol),适合成像目的。值得注意的是,[Ga]Ga-NODASA-PH1 在血浆中可稳定长达 2 小时,而 [Ga]Ga-NODASA-H8 在 30 分钟内降解。对于两种 Ga 肽,观察到全血细胞结合和血浆蛋白结合最小,表明具有良好的药物行为。[Ga]Ga-NODASA-PH1 是作为结核病特异性感染成像剂进行进一步的体外/体内评估的有前途的候选物。